Patient characteristics. All data are from the study start, defined as the first clinic visit wherein LDL-C, HDL-C, and TG measurements were taken, unless otherwise indicated.
| Variable | N (%), Mean (SD), or Median (min, max) |
|---|---|
| No. patients | 384 |
| Female | 345 (89.8) |
| Menopausalß | 132 (38.3% of female) |
| Race | |
| White | 246 (65.3) |
| Black | 46 (12.2) |
| Asian | 43 (11.4) |
| Other | 42 (11.1) |
| Coronary events | |
| MI | 6 |
| Angina | 15 |
| Sudden cardiac death | 0 |
| Total | 21 |
| Age, yrs, mean (SD) | |
| At diagnosis | 29.3 (12.7) |
| Study start | 41.6 (13.7) |
| Disease duration, yrs, mean (SD) | 12.2 (9.6) |
| SLEDAI-2K€ median, min, max | 4 (0, 51) |
| SLICC-DI# median, min, max | 1 (0, 3) |
| Corticosteroids | 246 (64.1) |
| Antimalarials£ | 238 (62.0) |
| Immunosuppressives¶ | 167 (43.5) |
| Hypertension¥ | 167 (43.5) |
| Elevated blood pressureη | 49 (21.9) |
| Hypercholesterolemia¢ | 160 (41.7) |
| Elevated cholesterolκ | 133 (34.6) |
| Diabetes§ | 23 (6.0) |
| Smoker$ | 46 (12.1) |
| Antihypertensive useϕ | 156 (93.4% of hypertensive) |
| Lipid-lowering medicationsΨ | 49 (30.6% of hypercholesterolemic) |
↵ß Minimum of 12 months amenorrhea, irrespective of cause.
↵€ Range 0 to 105, with higher scores indicating more active disease.
↵# Range 0 to 46, with higher scores indicating greater disease-related damage.
↵£ Include chloroquine and hydroxychloroquine.
↵¶ Include methotrexate, azathioprine, mycophenolate mofetil, cyclosporine, and cyclophosphamide.
↵¥ Diastolic blood pressure (BP) > 90 or systolic BP > 140 mm Hg, or treatment with antihypertensive medication.
↵η Diastolic BP > 90 or systolic BP > 140 mm Hg.
↵¢ Cholesterol ≥ 5.2 mmol/l or lipid-lowering therapy.
↵κ Cholesterol ≥ 5.2 mmol/l.
↵§ Fasting plasma glucose > 7.0 mmol/l or diabetes therapy.
↵$ Smoking an average of ≥ 1 cigarette/s per day over the past month.
↵ϕ All classes including diuretics, ß-blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, and angiotensin-type II receptor blockers.
↵Ψ HMG Co-A reductase inhibitors (statins). MI: myocardial infarction; SLEDAI-2K: Systemic Lupus Erythematosus Disease Activity Index 2000; SLICC-DI: Systemic Lupus International Collaborating Clinics Damage Index.